These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 39170618)

  • 21. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival.
    Rubio MT; Moreira-Teixeira L; Bachy E; Bouillié M; Milpied P; Coman T; Suarez F; Marcais A; Sibon D; Buzyn A; Caillat-Zucman S; Cavazzana-Calvo M; Varet B; Dy M; Hermine O; Leite-de-Moraes M
    Blood; 2012 Sep; 120(10):2144-54. PubMed ID: 22730537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in the treatment of graft-versus-host disease with immunomodulatory cells.
    Yu Q; Wang H; Zhang L; Wei W
    Int Immunopharmacol; 2021 Mar; 92():107349. PubMed ID: 33486323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Invariant natural killer T-cell subsets have diverse graft-versus-host-disease-preventing and antitumor effects.
    Maas-Bauer K; Lohmeyer JK; Hirai T; Ramos TL; Fazal FM; Litzenburger UM; Yost KE; Ribado JV; Kambham N; Wenokur AS; Lin PY; Alvarez M; Mavers M; Baker J; Bhatt AS; Chang HY; Simonetta F; Negrin RS
    Blood; 2021 Sep; 138(10):858-870. PubMed ID: 34036317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc.
    O'Neal J; Cooper ML; Ritchey JK; Gladney S; Niswonger J; González LS; Street E; Haas GJ; Carter A; Amayta PN; Gao F; Lee BH; Choi D; Berrien-Elliott M; Zhou A; Fehniger TA; Rettig MP; DiPersio JF
    Blood Adv; 2023 Oct; 7(20):6009-6022. PubMed ID: 37399471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.
    Chaidos A; Patterson S; Szydlo R; Chaudhry MS; Dazzi F; Kanfer E; McDonald D; Marin D; Milojkovic D; Pavlu J; Davis J; Rahemtulla A; Rezvani K; Goldman J; Roberts I; Apperley J; Karadimitris A
    Blood; 2012 May; 119(21):5030-6. PubMed ID: 22371885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells.
    Du J; Paz K; Thangavelu G; Schneidawind D; Baker J; Flynn R; Duramad O; Feser C; Panoskaltsis-Mortari A; Negrin RS; Blazar BR
    Blood; 2017 Jun; 129(23):3121-3125. PubMed ID: 28416503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Development of allogeneic CAR T-cells].
    Alcazer V; Depil S
    Bull Cancer; 2021 Oct; 108(10S):S73-S80. PubMed ID: 34920810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. iNKT: A new avenue for CAR-based cancer immunotherapy.
    Liu Y; Wang G; Chai D; Dang Y; Zheng J; Li H
    Transl Oncol; 2022 Mar; 17():101342. PubMed ID: 35063813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A party of three: iNKT cells in GVHD prevention.
    Heine A; Brossart P
    Blood; 2015 May; 125(22):3374-5. PubMed ID: 26022054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Culture-Expanded Human Invariant Natural Killer T Cells Suppress T-Cell Alloreactivity and Eradicate Leukemia.
    Schmid H; Schneidawind C; Jahnke S; Kettemann F; Secker KA; Duerr-Stoerzer S; Keppeler H; Kanz L; Savage PB; Schneidawind D
    Front Immunol; 2018; 9():1817. PubMed ID: 30127790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.
    Mehta RS; Rezvani K
    Front Immunol; 2018; 9():283. PubMed ID: 29497427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Graft-versus-Host Disease Modulation by Innate T Cells.
    Fang Y; Zhu Y; Kramer A; Chen Y; Li YR; Yang L
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy.
    Wolf BJ; Choi JE; Exley MA
    Front Immunol; 2018; 9():384. PubMed ID: 29559971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation.
    Bertaina A; Roncarolo MG
    Front Immunol; 2019; 10():1342. PubMed ID: 31354695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pre-transplant donor CD4
    Rubio MT; Bouillié M; Bouazza N; Coman T; Trebeden-Nègre H; Gomez A; Suarez F; Sibon D; Brignier A; Paubelle E; Nguyen-Khoc S; Cavazzana M; Lantz O; Mohty M; Urien S; Hermine O
    Leukemia; 2017 Apr; 31(4):903-912. PubMed ID: 27740636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of post-transplant mucosal-associated invariant T cell recovery on the development of acute graft-versus-host disease in allogeneic bone marrow transplantation.
    Kawaguchi K; Umeda K; Hiejima E; Iwai A; Mikami M; Nodomi S; Saida S; Kato I; Hiramatsu H; Yasumi T; Nishikomori R; Kondo T; Takaori-Kondo A; Heike T; Adachi S
    Int J Hematol; 2018 Jul; 108(1):66-75. PubMed ID: 29582333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer.
    Zhu Y; Smith DJ; Zhou Y; Li YR; Yu J; Lee D; Wang YC; Di Biase S; Wang X; Hardoy C; Ku J; Tsao T; Lin LJ; Pham AT; Moon H; McLaughlin J; Cheng D; Hollis RP; Campo-Fernandez B; Urbinati F; Wei L; Pang L; Rezek V; Berent-Maoz B; Macabali MH; Gjertson D; Wang X; Galic Z; Kitchen SG; An DS; Hu-Lieskovan S; Kaplan-Lefko PJ; De Oliveira SN; Seet CS; Larson SM; Forman SJ; Heath JR; Zack JA; Crooks GM; Radu CG; Ribas A; Kohn DB; Witte ON; Yang L
    Cell Stem Cell; 2019 Oct; 25(4):542-557.e9. PubMed ID: 31495780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human invariant natural killer T cells promote tolerance by preferential apoptosis induction of conventional dendritic cells.
    Schmid H; Ribeiro EM; Secker KA; Duerr-Stoerzer S; Keppeler H; Dong R; Munz T; Schulze-Osthoff K; Hailfinger S; Schneidawind C; Schneidawind D
    Haematologica; 2022 Feb; 107(2):427-436. PubMed ID: 33440919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.